

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

Sodium Nitrite Injection, USP
30 mg/mL

Antidote for acute cyanide poisoning

**HEALTH CANADA HAS AUTHORIZED THE SALE OF THIS EXTRAORDINARY
USE NEW DRUG FOR THE TREATMENT OF CYANIDE POISONING THAT IS
JUDGED TO BE LIFE-THREATENING BASED ON LIMITED CLINICAL TESTING
IN HUMANS**

Hope Pharmaceuticals Ltd.
552A Clarke Road, Suite 299
Coquitlam, BC V3J 0A3
Canada

Date of Preparation:
April 27, 2015

Submission Control No: <174143>

Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION.....	3
SUMMARY PRODUCT INFORMATION	3
INDICATIONS AND CLINICAL USE.....	3
CONTRAINDICATIONS	4
WARNINGS AND PRECAUTIONS.....	4
ADVERSE REACTIONS.....	8
DRUG INTERACTIONS	9
DOSAGE AND ADMINISTRATION	9
OVERDOSAGE	10
ACTION AND CLINICAL PHARMACOLOGY	11
STORAGE AND STABILITY.....	13
DOSAGE FORMS, COMPOSITION AND PACKAGING	13
PART II: SCIENTIFIC INFORMATION.....	14
PHARMACEUTICAL INFORMATION.....	14
CLINICAL TRIALS.....	14
ANIMAL PHARMACOLOGY.....	14
NON-CLINICAL TOXICOLOGY.....	15
REFERENCES	16
PART III: PATIENT MEDICATION INFORMATION	18

SODIUM NITRITE INJECTION, USP
30 mg/mL

PART I: HEALTH PROFESSIONAL INFORMATION

**HEALTH CANADA HAS AUTHORIZED THE SALE OF THIS EXTRAORDINARY
USE NEW DRUG FOR THE TREATMENT OF CYANIDE POISONING THAT IS
JUDGED TO BE LIFE-THREATENING BASED ON LIMITED CLINICAL TESTING
IN HUMANS**

SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form / Strength	Clinically Relevant Nonmedicinal Ingredients
Intravenous	Sodium nitrite injection, USP, 30 mg/mL	None <i>For a complete listing see Dosage Forms, Composition and Packaging section.</i>

INDICATIONS AND CLINICAL USE

Sodium Nitrite Injection is indicated for sequential use with sodium thiosulfate for the treatment of acute cyanide poisoning that is judged to be life-threatening. When the diagnosis of cyanide poisoning is uncertain, the potential risks associated with Sodium Nitrite Injection should be carefully weighed against the potential benefits, especially if the patient is not in extremis.

Cyanide poisoning may result from inhalation, ingestion, or dermal exposure to various cyanide-containing compounds, including smoke from closed-space fires. Sources of cyanide poisoning include hydrogen cyanide and its salts, cyanogenic plants, aliphatic nitriles, and prolonged exposure to sodium nitroprusside.

The presence and extent of cyanide poisoning are often initially unknown. There is no widely available, rapid, confirmatory cyanide blood test. Treatment decisions must be made on the basis of clinical history and signs and symptoms of cyanide intoxication. If clinical suspicion of cyanide poisoning is high, Sodium Thiosulfate Injection and Sodium Nitrite Injection should be administered without delay.

Table 1. Common Signs and Symptoms of Cyanide Poisoning

Symptoms	Signs
<ul style="list-style-type: none">• Headache• Confusion• Dyspnea• Chest Tightness• Nausea	<ul style="list-style-type: none">• Altered Mental Status (e.g., confusion, disorientation)• Seizures or Coma• Mydriasis• Tachypnea/Hyperpnea (early)• Bradypnea/Apnea (late)• Hypertension (early)/ Hypotension (late)• Cardiovascular Collapse• Vomiting• Plasma Lactate Concentration ≥ 8 mmol/L

In some settings, panic symptoms including tachypnea and vomiting may mimic early cyanide poisoning signs. The presence of altered mental status (e.g., confusion and disorientation) and/or mydriasis is suggestive of true cyanide poisoning although these signs can occur with other toxic exposures as well.

CONTRAINDICATIONS

None.

WARNINGS AND PRECAUTIONS

Sodium nitrite can cause serious adverse reactions and death in humans, even at doses less than twice the recommended therapeutic dose. Sodium nitrite causes hypotension and methemoglobin formation, which diminishes oxygen carrying capacity. Hypotension and methemoglobin formation can occur concurrently or separately. Because of these risks, sodium nitrite should be used to treat acute life-threatening cyanide poisoning and be used with caution in patients where the diagnosis of cyanide poisoning is uncertain.

Patients should be closely monitored to ensure adequate perfusion and oxygenation during treatment with sodium nitrite.

Alternative therapeutic approaches should be considered in patients known to have diminished oxygen or cardiovascular reserve (e.g. smoke inhalation victims, pre-existing anemia, cardiac or respiratory compromise), and those at higher risk of developing methemoglobinemia (e.g. congenital methemoglobin reductase deficiency) as they are at greater risk for potentially life-threatening adverse events related to the use of sodium nitrite.

Hypotension

Sodium nitrite has been associated with severe hypotension, methemoglobinemia, and death at doses less than twice recommended therapeutic doses. Hypotension may occur concurrently or

separately. Sodium nitrite should be used to treat life-threatening cyanide poisoning. When the diagnosis of cyanide poisoning is uncertain and/or the patient is not in extremis, special consideration should be given to administration of sodium nitrite if the patient is known or suspected to have diminished oxygen or cardiovascular reserve (e.g., smoke inhalation victims, pre-existing anemia, substantial blood loss, cardiac or respiratory compromise) or to be at higher risk of developing methemoglobinemia (e.g., congenital methemoglobin reductase deficiency).

Methemoglobinemia

Supportive care alone may be sufficient treatment without administration of antidotes for many cases of cyanide intoxication, particularly in conscious patients without signs of severe toxicity. Patients should be closely monitored to ensure adequate perfusion and oxygenation during treatment with sodium nitrite.

Methemoglobin levels should be monitored and oxygen administered during treatment with sodium nitrite whenever possible. When sodium nitrite is administered to humans a wide range of methemoglobin concentrations occur. Methemoglobin concentrations as high as 58% have been reported after two 300-mg doses of sodium nitrite administered to an adult. Sodium nitrite should be used with caution in the presence of other drugs that may cause methemoglobinemia such as procaine and nitroprusside. Sodium nitrite should be used with caution in patients who may be particularly susceptible to injury from vasodilation and its related hemodynamic sequelae. Hemodynamics should be monitored closely during and after administration of sodium nitrite, and infusion rates should be slowed if hypotension occurs.

Anemia

Sodium nitrite should be used with caution in patients with known anemia. Patients with anemia will form more methemoglobin (as a percentage of total hemoglobin) than persons with normal red blood cell (RBC) volumes. Optimally, these patients should receive a sodium nitrite dose that is reduced in proportion to their oxygen carrying capacity.

Smoke Inhalation Injury

Sodium nitrite should be used with caution in persons with smoke inhalation injury or carbon monoxide poisoning because of the potential for worsening hypoxia due to methemoglobin formation.

Neonates and Infants

Neonates and infants may be more susceptible than adults and older pediatric patients to severe methemoglobinemia when sodium nitrite is administered. Reduced dosing guidelines based on 6 mg/kg of body mass or 6-8 mL of 30 mg/mL solution per m² of body surface area should be followed in pediatric patients.⁶

G6PD Deficiency

Because patients with G6PD deficiency are at increased risk of a hemolytic crisis with sodium nitrite administration, alternative therapeutic approaches should be considered in these patients. Patients with known or suspected G6PD deficiency should be monitored for an acute drop in

hematocrit. Exchange transfusion may be needed for patients with G6PD deficiency who receive sodium nitrite.

Use with Other Drugs

Sodium nitrite should be used with caution in the presence of concomitant antihypertensive medications, diuretics or volume depletion due to diuretics, or drugs known to increase vascular nitric oxide, such as PDE5 inhibitors.

Incompatibility Information

Chemical incompatibility has been reported between Sodium Nitrite Injection and hydroxocobalamin and these drugs should not be administered simultaneously through the same IV line. No chemical incompatibility has been reported between sodium thiosulfate and sodium nitrite, when administered sequentially through the same IV line as described in Dosage and Administration.

Use with Other Cyanide Antidotes

Caution should be exercised when administering cyanide antidotes, other than sodium thiosulfate, simultaneously with Sodium Nitrite Injection, as the safety of co-administration has not been established. If a decision is made to administer another cyanide antidote, other than sodium thiosulfate, with Sodium Nitrite Injection, these drugs should not be administered concurrently in the same IV line.

Special Populations

Pregnant Women and Teratogenic Effects: Sodium nitrite is Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Sodium Nitrite Injection should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Sodium nitrite has caused fetal death in humans as well as animals. There are no studies in humans that have directly evaluated the potential reproductive toxicity of sodium nitrite. There are two epidemiological studies conducted in Australia that report a statistically significant increase in the risk for congenital malformations, particularly in the CNS, associated with maternal consumption of water containing nitrate levels in excess of 5 ppm.⁵ Results from a case-control study in Canada suggested a trend toward an increase in the risk for CNS malformations when maternal consumption of nitrate were ≥ 26 ppm (not statistically significant).¹

The potential reproductive toxicity of sodium nitrite exposure restricted to the prenatal period has been reported in guinea pigs, mice, and rats. There was no evidence of teratogenicity in guinea pigs, mice, or rats. However, sodium nitrite treatment of pregnant guinea pigs with 60 or 70 mg/kg/day resulted in abortion of the litters within 1-4 days of treatment. All animals treated subcutaneously with 70 mg/kg, sodium nitrite died within 60 minutes of treatment. Further studies demonstrated that a dose of 60 mg/kg resulted in measurable blood levels of methemoglobin in the dams and their fetuses for up to 6 hours post treatment. Maternal methemoglobin levels were higher than the levels in the offspring at all times measured. Based

on a dose comparison, a 60 mg/kg dose in the guinea pig that resulted in death was only 1.7 times higher than the highest clinical dose of sodium nitrite that would be used to treat cyanide poisoning.¹²

Studies testing prenatal and postnatal exposure have been reported in mice and rats. Treatment of pregnant rats via drinking water with sodium nitrite at concentrations of either 2000 or 3000 mg/L resulted in a dose-related increased mortality postpartum. This exposure regimen in the rat model would result in dosing of approximately 220 and 300 mg/kg/day (4.7 and 6.5 times the highest clinical dose of sodium nitrite that would be used to treat cyanide poisoning, based on a dose comparison).¹³

Sodium nitrite produces methemoglobin. Fetal hemoglobin is oxidized to methemoglobin more easily than adult hemoglobin. In addition, the fetus has lower levels of methemoglobin reductase than adults. Collectively, these data suggest that the human fetus would show greater sensitivity to methemoglobin resulting in nitrite-induced prenatal hypoxia leading to retarded development of certain neurotransmitter systems in the brain and long lasting dysfunction.

Nonteratogenic Effects: Behavioral and neurodevelopmental studies in rats suggest persistent effects of prenatal exposure to sodium nitrite that were detectable postnatally. Specifically, animals that were exposed prenatally to sodium nitrite demonstrated impaired discrimination learning behavior (both auditory and visual) and reduced long-term retention of the passive-avoidance response compared to control animals. Additional studies demonstrated a delay in the development of AchE and 5-HT positive fiber ingrowth into the hippocampal dentate gyrus and parietal neocortex during the first week of life of prenatal nitrite treated pups. These changes have been attributed to prenatal hypoxia following nitrite exposure.

Nursing Women: It is not known whether sodium nitrite is excreted in human milk. Because Sodium Nitrite Injection may be administered in life-threatening situations, breast-feeding is not a contraindication to its use. Because many drugs are excreted in human milk, caution should be exercised following Sodium Nitrite Injection administration to a nursing woman. There are no data to determine when breastfeeding may be safely restarted following administration of sodium nitrite. In studies conducted with Long-Evans rats, sodium nitrite administered in drinking water during pregnancy and lactation resulted in severe anemia, reduced growth and increased mortality in the offspring.

Labor and Delivery: It is not known whether sodium nitrite impacts uterine contractions or cervical dilatation during labor. Because Sodium Nitrite Injection may be administered in life-threatening situations, active labor is not a contraindication to its use.

Pediatrics (< 18 Years of Age): There are case reports in the medical literature of sodium nitrite in conjunction with sodium thiosulfate being administered to pediatric patients with cyanide poisoning; however, there have been no clinical studies to evaluate the safety or efficacy of sodium nitrite in the pediatric population. As for adult patients, dosing recommendations for pediatric patients have been based on theoretical calculations of antidote detoxifying potential, extrapolation from animal experiments, and a small number of human case reports.

Sodium nitrite must be used with caution in patients less than 6 months of age because they may be at higher risk of developing severe methemoglobinemia compared to older children and adults. The presence of fetal hemoglobin, which is oxidized to methemoglobin more easily than adult hemoglobin, and lower methemoglobin reductase levels compared to older children and adults may contribute to risk.

Mortality attributed to sodium nitrite was reported following administration of an adult dose (300 mg IV followed by a second dose of 150 mg) to a 17-month old child.³

Geriatrics (> 65 Years of Age): Sodium nitrite is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Renal Disease/Impairment: Sodium nitrite is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.

Hepatic Disease/Impairment: Sodium nitrite is not substantially excreted by the liver.

Monitoring and Laboratory Tests

Smoke Inhalation: Not all smoke inhalation victims will have cyanide poisoning and may present with burns, trauma, and exposure to other toxic substances making a diagnosis of cyanide poisoning particularly difficult. Prior to administration of Sodium Nitrite Injection smoke-inhalation victims should be assessed for the following:

- Exposure to fire or smoke in an enclosed area
- Presence of soot around the mouth, nose, or oropharynx
- Altered mental status

Although hypotension is highly suggestive of cyanide poisoning, it is only present in a small percentage of cyanide-poisoned smoke inhalation victims. Also indicative of cyanide poisoning is a plasma lactate concentration greater than or equal to 10 mmol/L (a value higher than that typically listed in the table of signs and symptoms of isolated cyanide poisoning because carbon monoxide associated with smoke inhalation also contributes to lactic acidemia). If cyanide poisoning is suspected, treatment should not be delayed to obtain a plasma lactate concentration.

ADVERSE REACTIONS

There have been no controlled clinical trials conducted to systematically assess the adverse events profile of sodium nitrite.

The medical literature has reported the following adverse events in association with sodium nitrite administration. These adverse events were not reported in the context of controlled trials or with consistent monitoring and reporting methodologies for adverse events. Therefore,

frequency of occurrence of these adverse events cannot be assessed.

Cardiovascular system: syncope, hypotension, tachycardia, methemoglobinemia, palpitations, dysrhythmia

Hematological: methemoglobinemia

Central nervous system: headache, dizziness, blurred vision, seizures, confusion, coma

Gastrointestinal system: nausea, vomiting, abdominal pain

Respiratory system: tachypnea, dyspnea

Body as a Whole: anxiety, diaphoresis, lightheadedness, injection site tingling, cyanosis, acidosis, fatigue, weakness, urticaria, generalized numbness and tingling

Severe hypotension, methemoglobinemia, cardiac dysrhythmias, coma and death have been reported in patients without life-threatening cyanide poisoning but who were treated with injection of sodium nitrite at doses less than twice those recommended for the treatment of cyanide poisoning.

DRUG INTERACTIONS

Formal drug interaction studies have not been conducted with Sodium Nitrite Injection.

DOSAGE AND ADMINISTRATION

Administration Recommendation

Comprehensive treatment of acute cyanide intoxication requires support of vital functions.

Administration of sodium nitrite and sodium thiosulfate should be considered adjunctive to appropriate supportive therapies. Airway, ventilatory and circulatory support, and oxygen administration should not be delayed to administer sodium nitrite and sodium thiosulfate.

Sodium nitrite injection and sodium thiosulfate injection are administered by slow intravenous injection. They should be given as early as possible after a diagnosis of acute life-threatening cyanide poisoning has been established. Sodium nitrite should be administered first, followed immediately by sodium thiosulfate. Blood pressure must be monitored during infusion in both adults and children. The rate of infusion should be decreased if significant hypotension is noted.

Age	Intravenous Dose of Sodium Nitrite and Sodium Thiosulfate ⁹
Adults (≥ 18 Years)	Sodium Nitrite -10 mL of sodium nitrite (300 mg/10 mL) at the rate of 2.5 to 5 mL/minute Sodium Thiosulfate - 50 mL of sodium thiosulfate (12.5 g/50 mL) immediately following administration of sodium nitrite.
Children (< 18 Years)	Sodium Nitrite -0.2 mL/kg (6 mg/kg or 6-8 mL/m ² BSA) of sodium nitrite (300 mg/10 mL) at the rate of 2.5 to 5 mL/minute not to exceed 10 mL Sodium Thiosulfate - 1 mL/kg of body weight (250 mg/kg or approximately 30-40 mL/m ² of BSA) of sodium thiosulfate (12.5 g/50 mL) not to exceed 50 mL total dose immediately following administration of sodium nitrite.

NOTE: If signs of poisoning reappear, repeat treatment using one-half the original dose of both sodium nitrite and sodium thiosulfate.

In adult and pediatric patients with known anemia, it is recommended that the dosage of sodium nitrite should be reduced proportionately to the hemoglobin concentration.

All parenteral drug products should be inspected *visually* for particulate matter and discoloration prior to administration, whenever solution and container permit. Solutions showing haziness, particulate matter, discoloration, etc., should not be used. Discard unused portion.

Recommended Monitoring

Patients should be monitored for at least 24-48 hours after Sodium Nitrite Injection administration for adequacy of oxygenation and perfusion and for recurrent signs and symptoms of cyanide toxicity. When possible, hemoglobin/hematocrit should be obtained when treatment is initiated. Measurements of oxygen saturation using standard pulse oximetry and calculated oxygen saturation values based on measured PO₂ are unreliable in the presence of methemoglobinemia.

Methemoglobin Level: Administration of sodium nitrite solely to achieve an arbitrary level of methemoglobinemia may be unnecessary and potentially hazardous. The therapeutic effects of sodium nitrite do not appear to be mediated by methemoglobin formation alone and clinical responses to sodium nitrite administrations have been reported in associated with methemoglobin levels of less than 10%. Administration of sodium nitrite beyond the initial dose should be guided primarily by clinical response to treatment (i.e. a second dose should be considered only if there is inadequate clinical response to the first dose). It is generally recommended that methemoglobin concentrations be closely monitored and kept below 30%. Serum methemoglobin levels should be monitored during treatment using co-oximetry, and administration of sodium nitrite should generally be discontinued when methemoglobin levels exceed 30%. Intravenous methylene blue and exchange transfusion have been reported in the literature as treatments for life-threatening methemoglobinemia.

Blood Pressure: blood pressure must be monitored during infusion of sodium nitrite in both adults and children. The rate of infusion should be decreased if significant hypotension is noted.

OVERDOSAGE

Large doses of sodium nitrite result in severe hypotension and toxic levels of methemoglobin which may lead to cardiovascular collapse.

Sodium nitrite administration has been reported to cause or significantly contribute to mortality in adults at oral doses as low as 1 g and intravenous doses as low as 600 mg. A death attributed to sodium nitrite has been reported following administration of an adult dose (300 mg IV followed by a second dose of 150 mg) to a 17-month old child.³

Cyanosis may become apparent at a methemoglobin level of 10-20%. Other clinical signs and symptoms of sodium nitrite toxicity (anxiety, dyspnea, nausea, and tachycardia) can be apparent at methemoglobin levels as low as 15%. More serious signs and symptoms, including cardiac dysrhythmias, circulatory failure, and central nervous system depression are seen as methemoglobin levels increase, and levels above 70% are usually fatal.

Treatment of overdose involves supplemental oxygen and supportive measures such as exchange transfusion. Treatment of severe methemoglobinemia with intravenous methylene blue has been described in the medical literature; however, this may also cause release of cyanide bound to methemoglobin. Because hypotension appears to be mediated primarily by an increase in venous capacitance, measures to increase venous return may be most appropriate to treat hypotension.

For management of a suspected drug overdose, contact your regional Poison Control Centre.

HEALTH CANADA HAS AUTHORIZED THE SALE OF THIS EXTRAORDINARY USE NEW DRUG FOR THE TREATMENT OF CYANIDE POISONING THAT IS JUDGED TO BE LIFE-THREATENING BASED ON LIMITED CLINICAL TESTING IN HUMANS

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

Exposure to a high dose of cyanide can result in death within minutes due to the inhibition of cytochrome oxidase resulting in arrest of cellular respiration. Specifically, cyanide binds rapidly with cytochrome a₃, a component of the cytochrome c oxidase complex in mitochondria. Inhibition of cytochrome a₃ prevents the cell from using oxygen and forces anaerobic metabolism, resulting in lactate production, cellular hypoxia and metabolic acidosis. In massive acute cyanide poisoning, the mechanism of toxicity may involve other enzyme systems as well.

The synergy resulting from treatment of cyanide poisoning with the combination of sodium nitrite and sodium thiosulfate is the result of differences in their primary mechanisms of action as antidotes for cyanide poisoning.²

Sodium Nitrite

Sodium nitrite is thought to exert its therapeutic effect by reacting with hemoglobin to form methemoglobin, an oxidized form of hemoglobin incapable of oxygen transport but with high affinity for cyanide.¹¹ Cyanide preferentially binds to methemoglobin over cytochrome a₃, forming the nontoxic cyanomethemoglobin. Methemoglobin displaces cyanide from cytochrome oxidase, allowing resumption of aerobic metabolism. The chemical reaction is as follows:

$\text{NaNO}_2 + \text{Hemoglobin} \rightarrow \text{Methemoglobin}$


$\text{HCN} + \text{Methemoglobin} \rightarrow \text{Cyanomethemoglobin}$

Vasodilation has also been cited to account for at least part of the therapeutic effect of sodium nitrite. It has been suggested that sodium nitrite-induced methemoglobinemia may be more

efficacious against cyanide poisoning than comparable levels of methemoglobinemia induced by other oxidants. Also, sodium nitrite appears to retain some efficacy even when the formation of methemoglobin is inhibited by methylene blue.¹¹

Sodium Thiosulfate

The primary route of endogenous cyanide detoxification is by enzymatic transulfuration to thiocyanate (SCN⁻), which is relatively nontoxic and readily excreted in the urine. Sodium thiosulfate is thought to serve as a sulfur donor in the reaction catalyzed by the enzyme rhodanese, thus enhancing the endogenous detoxification of cyanide in the following chemical reaction:



Pharmacodynamics

When 4 mg/kg sodium nitrite was administered intravenously to six healthy human volunteers, the mean peak methemoglobin concentration was 7%, achieved at 30-60 minutes after injection, consistent with reports in cyanide poisoning victims. Supine systolic and diastolic blood pressures dropped approximately 20% within 10 minutes, a drop which was sustained throughout the 40 minutes of testing. This was associated with a 20 beat per minute increase in pulse rate that returned to baseline in 10 minutes. Five of these subjects were unable to withstand orthostatic testing due to fainting. One additional subject, who received a 12 mg/kg dose of sodium nitrite, experienced severe cardiovascular effects and achieved a peak methemoglobin concentration of 30% at 60 minutes following injection.

Oral doses of 120 to 180 mg of sodium nitrite administered to healthy volunteers caused minimal cardiovascular changes when subjects were maintained in the horizontal position. However, minutes after being placed in the upright position subjects exhibited tachycardia and hypotension with syncope.

The half life for conversion of methemoglobin to normal hemoglobin in a cyanide poisoning victim who has been administered sodium nitrite is estimated to be 55 minutes.

Pharmacokinetics

Sodium Nitrite

Sodium nitrite is a strong oxidant, and reacts rapidly with hemoglobin to form methemoglobin. The pharmacokinetics of free sodium nitrite in humans have not been well studied. It has been reported that approximately 40% of sodium nitrite is excreted unchanged in the urine while the remaining 60% is metabolized to ammonia and related small molecules.

Cyanide

The apparent terminal elimination half life and volume of distribution of cyanide, in a patient treated for an acute cyanide poisoning with sodium nitrite and sodium thiosulfate administration, have been reported to be 19 hours and 0.41 L/kg, respectively. Additionally, an initial elimination half life of cyanide has been reported to be approximately 1-3 hours.

Thiocyanate

After detoxification, in healthy subjects, thiocyanate is excreted mainly in the urine at a rate inversely proportional to creatinine clearance. In healthy subjects, the elimination half-life and volume of distribution of thiocyanate have been reported to be 2.7 days and 0.25 L/kg, respectively. However, in subjects with renal insufficiency the reported elimination half life is approximately 9 days.

STORAGE AND STABILITY

Store at room temperature between 15° to 30°C (59 to 86°F). Single dose vial, discard unused portion. Protect from direct light. Do not permit to freeze.

DOSAGE FORMS, COMPOSITION AND PACKAGING

Sodium Nitrite Injection, USP is a sterile clear aqueous solution with a pH between 7.0 and 9.0; and is intended for intravenous injection.

Each vial contains 300 mg of sodium nitrite in 10 mL water for injection (3% or 30 mg/mL).

Supplied as one single dose 10 mL vial in a carton.

*

PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance


Proper name: Sodium nitrite

Chemical name: nitrous acid sodium salt

Molecular formula and molecular mass: NaNO_2

Molecular mass: 69.0

Structural formula:



Physicochemical properties: Sodium nitrite is a white to off-white solid that is hygroscopic, soluble in water and slightly soluble in alcohol

CLINICAL TRIALS

The human data supporting the use of sodium nitrite for cyanide poisoning consists primarily of published case reports. There are no randomized controlled clinical trials. Nearly all the human data describing the use of sodium nitrite report its use in conjunction with sodium thiosulfate. Dosing recommendations for humans have been based on theoretical calculations of antidote detoxifying potential, extrapolation from animal experiments, and a small number of human case reports.

There have been no human studies to prospectively and systematically evaluate the safety of sodium nitrite or sodium thiosulfate in humans. Available human safety information is based largely on anecdotal case reports and case series of limited scope.

ANIMAL PHARMACOLOGY

Due to the extreme toxicity of cyanide, experimental evaluation of treatment efficacy has predominantly been completed in animal models. Chen et al. reported the superior efficacy of the combination of sodium nitrite and sodium thiosulfate in 1933. Treatment consisted of intravenously administered 22.5 mg/kg (half the lethal dose) sodium nitrite or 1 g/kg sodium thiosulfate alone or in sequence immediately after subcutaneous injection of sodium cyanide into dogs over a range of doses. Subsequent doses of 10 mg/kg sodium nitrite and/or 0.5 g/kg sodium

thiosulfate were administered when clinical signs or symptoms of poisoning persisted or reappeared. Either therapy administered alone increased the dose of sodium cyanide required to cause death, and when administered together, sodium nitrite and sodium thiosulfate resulted in a synergistic effect in raising the lethal dose of sodium cyanide.⁴ The combined therapy appeared to have reduced efficacy when therapy was delayed until signs of poisoning (e.g. convulsions) appeared; however, other investigators have reported survival in dogs that were administered antidotal treatment after respiratory arrest had occurred.

Animal studies conducted in other species (e.g., rat, guinea pig, sheep, pigeon and cat) have also supported a synergistic effect of intravenous sodium nitrite and sodium thiosulfate in the treatment of cyanide poisoning.

While intravenous injection of sodium nitrite and sodium thiosulfate was effective in reversing the effects of lethal doses of cyanide in dogs, intramuscular injection of sodium nitrite, with or without sodium thiosulfate, was found not to be effective in the same setting.¹⁰

NON-CLINICAL TOXICOLOGY

Carcinogenesis, Mutagenesis, Impairment of Fertility

The potential benefit of an acute exposure to sodium nitrite as part of a cyanide antidote outweighs concerns raised by the equivocal findings in chronic rodent studies. Sodium nitrite (0, 750, 1500, or 3000 ppm equivalent to average daily doses of approximately 0, 35, 70, or 130 mg/kg for males and 0, 40, 80, or 150 mg/kg for females) was orally administered to rats (Fischer 344 strain) for 2 years via drinking water. There were no significant increases in the incidence of tumor in either male or female rats. Sodium nitrite (0, 750, 1500, or 3000 ppm equivalent to average daily doses of approximately 0, 60, 120, or 220 mg/kg for males and 0, 45, 90, or 165 mg/kg for females) was administered to B6C3F1 mice for 2 years via the drinking water. Equivocal results were obtained in female mice. Specifically, there was a positive trend toward an increase in the incidence of squamous cell papilloma or carcinoma in the forestomach of female mice. Although the incidence of hyperplasia of the glandular stomach epithelium was significantly greater in the high-dose male mice compared to controls, there were no significant increases in tumors in the male mice.⁸ Numerous reports in the published literature indicate that sodium nitrite may react *in vivo* with secondary amines to form carcinogenic nitrosamines in the stomach. Concurrent exposure to sodium nitrite and secondary amines in feed or drinking water resulted in an increase in the incidence of tumors in rodents.¹²

Mutagenesis:

Sodium nitrite is mutagenic in *S. typhimurium* strains TA100, TA1530, TA1535 with and without metabolic activation; however, it was negative in strain TA98, TA102, DJ460 and *E. coli* strain WP2UVRA/PKM101. Sodium nitrite has been reported to be genotoxic to V79 hamster cells *in vitro* and in the mouse lymphoma assay, both assays conducted in the absence of metabolic activation. Sodium nitrite was negative in the *in vitro* chromosomal aberrations assay using human peripheral blood lymphocytes. Acute administration of sodium nitrite to male rats or male mice did not produce an increased incidence of micronuclei in bone marrow.

Likewise, sodium nitrite administration to mice for 14-weeks did not result in an increase in the incidence of micronuclei in the peripheral blood.

Fertility:

Clinical studies to evaluate the potential effects of sodium nitrite intake on fertility of either males or females have not been reported. In contrast, multigenerational fertility and reproduction studies conducted by the National Toxicology Program did not detect any evidence of an effect of sodium nitrite (0.0, 0.06, 0.12, and 0.24% weight/volume) on either fertility or any reproductive parameter in Swiss CD-1 mice. This treatment protocol resulted in approximate doses of 125, 260, and 425 mg/kg/day. The highest exposure in this mouse study is 4.6 times greater than the highest clinical dose of sodium nitrite that would be used to treat cyanide poisoning (based on a dose comparison).⁷

REFERENCES

1. Arbuckle T, Sherman G, Corey P, Walters D, Lo B. Water nitrates and CNS birth defects: a population-based case-control study. *Arch Environ Health* 1988;43(2):162-7.
2. Baskin, S., et al. The antidotal action of sodium nitrite and sodium thiosulfate against cyanide poisoning. *Journal of Clinical Pharmacology*. 1992; 32: 368-375.
3. Berlin C. Treatment of cyanide poisoning in children. *Pediatrics*. 1970; 46(5): 763-765.
4. Chen, K., et al. Methylene Blue, Nitrites, and Sodium Thiosulfate against cyanide poisoning. *Proceedings of the Society for Experimental Biology and Medicine*. 1933; 31(2): 250-253.
5. Dorsch MM, Scragg RKR, McMichael AJ, Baghurst PA, Dyer KF. Congenital malformations and maternal drinking water supply in rural South Australia: a case-control study. *Am J Epidemiol* 1984;119(4):473-86.
6. National Center for Disaster Preparedness. Pediatric preparedness for disasters and terrorism: A national consensus conference. 2003.
7. National Toxicology Program. United States National Institute of Environmental Health Sciences. Final report on the reproductive toxicity of sodium nitrite (CAS no. 7632-00-0) in CD-1-swiss mice. National Toxicology Program. 1990.
8. National Toxicology Program. United States National Institute of Environmental Health Sciences. NTP technical report on the toxicology and carcinogenesis studies of sodium nitrite (CAS no. 7632-00-0) in F344/N rats and B6C3F1 mice (drinking water studies. National Toxicology Program. 2001.
9. U.S Food and Drug Administration 2012: Sodium Thiosulfate Label Information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203922s000lbl.pdf

10. Vick, J.A. and Froehlich H. Treatment of cyanide poisoning. *Military Medicine* 1991; 156(7): 330-339.
11. Way, J. et al. Recent Perspectives on the Toxicodynamic Basis of Cyanide Antagonism. *Fundamental and Applied Toxicology*. 1984, 4:S231-S239.
12. World Health Organization. Nitrite (and potential endogenous formation of N-nitroso compounds. WHO Food Additives Series 35. 1996.
13. Roth A, Herkert G, Bercz J, Smith M. Evaluation of the developmental toxicity of sodium nitrite in Long-Evans rats. *Fundamental and Applied Toxicology*. 9: 668-677; 1987.

PART III: PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION

SODIUM NITRITE INJECTION, USP 30 mg/mL

Read this carefully before you start taking Sodium Nitrite Injection. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about Sodium Nitrite Injection.

**HEALTH CANADA HAS AUTHORIZED THE SALE OF THIS EXTRAORDINARY
USE NEW DRUG FOR THE TREATMENT OF CYANIDE POISONING THAT IS
JUDGED TO BE LIFE-THREATENING BASED ON LIMITED CLINICAL TESTING
IN HUMANS**

ABOUT THIS MEDICATION

What the medication is used for:

Sodium Nitrite Injection is used as an antidote for cyanide poisoning. Cyanide poisoning is a condition that develops when you inhale, touch, or swallow cyanide. Cyanide is a poisonous chemical that prevents your body from absorbing oxygen. The lack of oxygen can damage your organs and be life-threatening.

How does sodium nitrite injection work?:

Sodium Nitrite Injection works by helping to prevent cyanide from binding to important enzymes in the cells of your body, allowing you to continue breathing.

What the medicinal ingredient is:

Sodium nitrite

What the non-medicinal ingredients are:

Water

Sodium Nitrite Injection comes in the following dosage form:

Each 10 mL vial of Sodium Nitrite Injection contains 300 mg of the active ingredient sodium nitrite (30 mg/mL).

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions:

Sodium nitrite can cause serious adverse reactions and death in humans, even at doses less than twice the recommended therapeutic dose. Sodium nitrite causes low blood pressure and methemoglobin formation in blood, which reduces the ability of blood to carry oxygen. Low blood pressure and methemoglobin formation can occur at the same time or separately and can cause harm. Due to these risks, the healthcare professional will decide whether to use this antidote.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you are administered Sodium Nitrite Injection. Talk about any health conditions you may have including if you:

- have kidney problems;
- are pregnant or breast-feeding;
- have low blood pressure;
- have a condition called anemia (This is a reduction in number of red blood cells in the bloodstream. Anemia can make the skin appear pale and can cause weakness or breathlessness);
- suffer from Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency (This may result in anemia.);
- have a history of elevated levels of methemoglobin (This is a modified form of hemoglobin that reduces the amount of oxygen in the bloodstream and can cause weakness or breathlessness.);
- have inhaled smoke from a fire;

INTERACTIONS WITH THIS MEDICATION

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements, or alternative medicines.

The following medicines have side effects that are similar to the side effects that may occur with sodium nitrite.

- Other cyanide antidotes;
- Medicines used to treat high blood pressure such as beta blockers, diuretics, and nitrates;
- Medicines that can increase methemoglobin levels such as procaine (used as a local anesthetic) and nitroprusside (used to reduce blood pressure)

It may be necessary for your doctor to adjust the dose of sodium nitrite or one of your other medications.

Sodium nitrite should not be taken at the same time as hydroxocobalamin through the same intravenous line as compatibility of the products is not known.

HOW SODIUM NITRITE INJECTION IS ADMINISTERED

Usual dose:

Sodium nitrite will be given by injection into a vein by a doctor or nurse. Your doctor will choose the dose that is right for you and may monitor your blood pressure after injection. If signs of cyanide poisoning reappear, your doctor will decide if you should receive more sodium nitrite. Your doctor will monitor your condition 24-48 hours after injection and may run blood tests.

Overdose:

Overdosing is unlikely. If it does happen, your doctor will treat any symptoms that follow.

If you think you have taken too much sodium nitrite, contact your healthcare professional, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

WHAT ARE THE POSSIBLE SIDE EFFECTS FROM USING SODIUM NITRITE INJECTION?

Like all medicines, this medicine can cause side effects, although not everybody gets them.

The side effects of sodium nitrite include:

- Cardiovascular: reduced blood pressure, rapid heart rate, irregular pulse, fainting, palpitations
- Blood disorder: oxygen deprivation in tissues (methemoglobinemia)
- Central nervous system: headache, dizziness, blurred vision, seizures, confusion, coma
- Psychiatric: anxiety
- Gastrointestinal: nausea, vomiting, abdominal pain
- Respiratory: rapid breathing, shortness of breath
- Skin: urticaria (skin rash notable for pale, red, raised, itchy bumps)
- Body as a whole: sweating, light headedness, injection site tingling, fatigue, weakness, generalized numbness and tingling, blue or purple colored skin

The frequencies at which the above reactions occur are not known yet.

Death was reported after administration of a dose of sodium nitrite that was higher than the recommended therapeutic dose, but less than twice the recommended therapeutic dose.

These are not all the possible side effects you may feel when taking Sodium Nitrite Injection. If you experience any side effects not listed here, contact your healthcare professional. Please also see **Warnings and Precautions**.

If you get any side effects, or they become troublesome, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.

HOW TO STORE IT

The healthcare professional will store the product at room temperature 15° to 30°C (59 to 86°F).

Reporting Side Effects

You can help improve the safe use of health products for Canadians by reporting serious and unexpected side effects to Health Canada. Your report may help to identify new side effects and change the product safety information.

3 ways to report:

- Online at [MedEffect](#);
- By calling 1-866-234-2345 (toll-free);
- By completing a Consumer Side Effect Reporting Form and sending it by:
 - Fax to 1-866-678-6789 (toll-free), or
 - Mail to: Canada Vigilance Program
Health Canada, Postal Locator 0701E
Ottawa, ON
K1A 0K9Postage paid labels and the Consumer Side Effect Reporting Form are available at [MedEffect](#).

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

If you want more information about Sodium Nitrite:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the [Health Canada website](#); the manufacturer's website www.nitrite.ca, or by calling 1-800-755-9595.

This leaflet was prepared by:
Hope Pharmaceuticals, Ltd.
522A Clarke Road, Suite 299
Coquitlam, BC V3J 0A3
Canada

Last revised: April 27, 2015